TNF-alpha / TNF-beta (lymphotoxin-alpha)

Class

TNF receptor (p75)-Fc fusion protein (etanercept, liquid/pre-filled formulation)

Pathway

Soluble decoy receptor that binds and neutralizes circulating TNF before receptor engagement

Tumor necrosis factor-alpha (TNF-alpha) and its relative lymphotoxin-alpha (formerly TNF-beta) are cytokines, small signaling proteins produced mainly by immune cells, that drive inflammation by binding to TNF receptors on target cells and triggering downstream pathways that promote cell activation, recruitment of additional immune cells, and tissue-damaging inflammatory responses. In chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, TNF signaling becomes persistently elevated, sustaining joint destruction, skin plaques, or gut inflammation. One therapeutic strategy is to construct a soluble decoy receptor: a fusion protein combining the extracellular, ligand-binding portion of the p75 TNF receptor with the constant region of an antibody (Fc domain). This engineered protein circulates in the blood, binds free TNF-alpha and lymphotoxin-alpha before they can engage cell-surface receptors, and thereby neutralizes their inflammatory signal upstream of receptor activation. Because it acts as a decoy rather than blocking receptors directly on cells, it reduces systemic inflammatory tone without requiring cell-surface receptor occupancy. This mechanism broadly matters wherever TNF-driven inflammation underlies tissue damage, and it represents one of the original validated approaches to biologic immunomodulation in autoimmune and inflammatory disease.